In this three-part series of discussions with top experts in clinical development for rare disease and orphan indications, Medpace, along with industry partners, will address some of the key challenges, opportunities, and considerations for conducting research in this dynamic and complex area of research.
Read More
We are delighted to announce our participation in Rare Disease Day for another consecutive year. In addition to our internal activities, Medpace will be hosting a webinar on how advanced therapies are dramatically changing the way patients are treated for a wide variety of diseases – particularly for patients with rare diseases and orphan indications.
Read More
In our previous post, we discussed how patient-focused clinical trial design and collaborative approaches to site enrollment can accelerate rare disease clinical research. Yet, as our presenters emphasized in the presentation, the only way to ensure that trials are being conducted in a truly-patient focused way is to hear directly from rare disease patients and their families. In this post we summarize the insights from Beth Woelfel Harvey, a parent of a child with Duchenne muscular dystrophy (DMD).
Read More
A few months ago, Medpace and the Cincinnati Children’s Hospital Medical Center presented a webinar on the importance of patient-centric clinical research. Over the next several weeks, we will build off each topic that was addressed during the presentation. In this post, we take a look at what patient-centric clinical trial design looks like for these studies.
Read More
Richard Scheyer, MD, Vice President, Medical Affairs at Medpace answers some questions about his upcoming presentation about CNS-targeted therapies at DIA 2018.
Read More
In our previous post, we discussed the approaches to help you identify, enroll and retain rare disease populations in clinical trials. Once the right patients have been enrolled in the trial, the challenge becomes measuring the efficacy of the experimental treatment and determining whether it’s producing the desired effect. However, invasive drug delivery methods, such as IV injection, can complicate this measurement and establishing whether the therapy actually reaches the target tissue can be difficult.
Read More
Enrolling enough subjects into a rare disease study can seem like an insurmountable challenge, especially when you’re looking at a subset of a rare disease, or an ultra-rare disease population. By mapping out your path, you can mitigate many potential issues. There are two key concepts: A patient-centric approach and referral networks.
Read More
In Part 1 of a 3 part blog series, we will explore how the heritability of neurological diseases and psychiatric diseases is changing the clinical development landscape. From there, we will take a look at new genetic findings in a number of different diseases and how these findings are making us rethink our broad view of how we ought to approach these diseases. Finally, we will explore the history of treatment of rare diseases with CNS manifestations, touching on both successes and failures.
Read More
Duchenne Muscular Dystrophy (DMD) is a specific type of muscular dystrophy characterized by muscle weakness and deterioration. DMD research comes with its fair share of challenges, especially with pediatric trials. We’ll go into a few of these challenges and how Medpace is positioned to overcome them.
Read More
As a full service, global CRO with an integrated central lab, Medpace has the scientific, operational and regulatory expertise to manage your celiac disease clinical trial.
Read More